利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.016 秒)

    Cell-specific adenovirus vector comprising EBV-specific promoter
    4.
    发明授权
    Cell-specific adenovirus vector comprising EBV-specific promoter 失效
    包含EBV特异性启动子的细胞特异性腺病毒载体

    公开(公告)号：US07371570B2

    公开(公告)日：2008-05-13

    申请号：US10698160

    申请日：2003-10-30

    申请人： De Chao Yu ,  Nagarajan Ramesh

    发明人： De Chao Yu ,  Nagarajan Ramesh

    IPC分类号： C12N15/861 ,  C12N5/10 ,  A61K48/00

    CPC分类号： C12N15/86 ,  A61K38/00 ,  A61K48/00 ,  C07K14/005 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2710/16222 ,  C12N2830/00 ,  C12N2830/205 ,  C12N2830/30 ,  C12N2830/60 ,  C12N2840/203

    摘要： Replication-competent adenoviral vectors comprising an EBV-specific transcriptional regulatory element (TRE) operably linked to a gene required for adenovirus replication are provided. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication can be restricted to particular target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.

    摘要翻译： 提供了包含可操作地连接到腺病毒复制所需的基因的EBV特异性转录调控元件（TRE）的复制能力的腺病毒载体。 通过提供依赖于仅在特定的有限细胞类型中活跃的转录因子的转录起始调节，病毒复制可以限于特定的靶细胞。 修饰的腺病毒可以用作引入新遗传能力的载体，特别是与用于治疗瘤形成的细胞毒性有关。

    Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
    6.
    发明申请
    Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium 审中-公开
    通过膀胱上皮增强治疗剂吸收的组合物和方法

    公开(公告)号：US20050059613A1

    公开(公告)日：2005-03-17

    申请号：US10885309

    申请日：2004-07-07

    申请人： Bahram Memarzadeh ,  Nagarajan Ramesh ,  David Frey ,  DeChao Yu

    发明人： Bahram Memarzadeh ,  Nagarajan Ramesh ,  David Frey ,  DeChao Yu

    IPC分类号： A61K20060101 ,  A61K31/70 ,  A61K31/7012 ,  A61K31/7024 ,  A61K31/715

    CPC分类号： A61K31/70 ,  A61K31/7012 ,  A61K31/7024 ,  A61K31/715

    摘要： Compositions and methods for enhancing introduction of therapeutic agents into the bladder epithelium for the treatment of bladder diseases and disorders such as bladder cancer are described. According to one method, the luminal surface of the bladder is contacted with a composition comprising a bladder enhancer and a therapeutic agent for the treatment of the bladder disease. According to an alternative method, the luminal surface of the bladder is first contacted with a pretreatment composition comprising a bladder enhancer and subsequently contacted with a composition comprising a therapeutic agent for the treatment of the bladder disease. The transduction enhancing agent can be a mono-, di-, or poly-saccharide having a lipophilic substituent such as n-dodecyl-β-D-maltoside (DDM). Compositions comprising a transduction enhancing agent and a therapeutic agent for the treatment of a bladder disease are also described.

    摘要翻译： 描述了用于增强将治疗剂引入膀胱上皮以治疗膀胱疾病和疾病如膀胱癌的组合物和方法。 根据一种方法，膀胱的管腔表面与包含膀胱增强剂和治疗膀胱疾病的治疗剂的组合物接触。 根据另一种方法，首先将膀胱的腔表面与包含膀胱增强剂的预处理组合物接触，随后与包含用于治疗膀胱疾病的治疗剂的组合物接触。 转导增强剂可以是具有亲脂性取代基如正十二烷基-β-D-麦芽糖苷（DDM）的单糖，二糖或多糖。 还描述了包含转导增强剂和用于治疗膀胱疾病的治疗剂的组合物。

    Compositions and methods for treating diabetes
    9.
    发明授权
    Compositions and methods for treating diabetes 失效
    治疗糖尿病的组合物和方法

    公开(公告)号：US06537806B1

    公开(公告)日：2003-03-25

    申请号：US09185852

    申请日：1998-11-04

    申请人： William R. A. Osborne ,  Nagarajan Ramesh

    发明人： William R. A. Osborne ,  Nagarajan Ramesh

    IPC分类号： C12N500

    CPC分类号： C12N5/069 ,  A61K35/12 ,  A61K38/28 ,  A61K48/00 ,  C12N2510/02 ,  Y10S424/81 ,  Y10S514/866

    摘要： The present invention provides an isolated population of cells containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention also provides an isolated population of cells which further express a hexosamine synthetic pathway enzyme. The invention additionally provides vectors containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention further provides a method of treating or preventing diabetes by implanting into an individual cells coexpressing proinsulin containing a proinsulin cleavage site and a glucose-regulated protease capable of cleaving the proinsulin cleavage site to produce insulin.

    摘要翻译： 本发明提供了分离的细胞群，其含有含有胰岛素原切割位点的可表达核酸的胰岛素原，以及编码能够切割胰岛素原切割位点产生胰岛素的蛋白酶的葡萄糖调节的可表达核酸。 本发明还提供进一步表达己糖胺合成途径酶的分离的细胞群。 本发明另外提供含有编码含有胰岛素原切割位点的胰岛素原的可表达核酸的载体和编码能够切割胰岛素原切割位点产生胰岛素的蛋白酶的葡萄糖调节的可表达核酸。 本发明还提供了一种通过植入含有胰岛素原切割位点的共表达胰岛素原的单个细胞和能够切割胰岛素原切割位点产生胰岛素的葡萄糖调节的蛋白酶来治疗或预防糖尿病的方法。